36823-82-2

Basic information

• Product Name: 4-isopropoxybenzoyl chloride
• Synonyms: 4-(1-Methylethoxy)benzoic acid chloride;benzoyl chloride, 4-(1-methylethoxy)-
• CAS NO: 36823-82-2
• Molecular Formula: C₁₀H₁₁ClO₂
• Molecular Weight: 198.65
• EINECS: 253-229-5
• Mol File: 36823-82-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 286.8°C at 760 mmHg
• Flash Point: 106.8°C
• Appearance: /
• Density: 1.146g/cm³
• Vapor Pressure: 0.00259mmHg at 25°C
• Refractive Index: 1.516
• CAS DataBase Reference: 4-isopropoxybenzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-isopropoxybenzoyl chloride(36823-82-2)
• EPA Substance Registry System: 4-isopropoxybenzoyl chloride(36823-82-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 36823-82-2(Hazardous Substances Data)

Usage

General Description

4-Isopropoxybenzoyl chloride is a chemical compound with the formula C10H11ClO2. It is an aromatic benzoyl chloride derivative with an isopropoxy group attached to the benzene ring. 4-Isopropoxybenzoyl chloride is commonly used as a reagent in organic synthesis, particularly in the preparation of pharmaceuticals and agrochemicals. It is a versatile building block in the production of various esters, amides, and other functionalized compounds. 4-Isopropoxybenzoyl chloride is a reactive compound and should be handled with caution, as it can cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C10H11ClO2/c1-7(2)13-9-5-3-8(4-6-9)10(11)12/h3-7H,1-2H3

Upstream product

• 99-96-7 4-hydroxy-benzoic acid 
• 122488-52-2 ethyl 4-isopropoxybenzoate 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 13205-46-4 4-isopropoxybenzoic acid 

Downstream Products

• 5411-23-4 4-isopropoxy-benzoic acid-[2-(2-methyl-pyrrolidino)-ethyl ester] 
• 96327-38-7 5-(4-Isopropoxy-benzoyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid 
• 96326-96-4 5-(4-Isopropoxy-benzoyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid isopropyl ester 
• 1440967-48-5 C₂₈H₂₉N₃O₆S 
• 1422358-08-4 C₂₅H₂₆N₂O₄ 
• 877635-58-0 C₂₀H₁₈N₂O₅S 
• 1393713-27-3 C₁₈⁽¹³⁾CH₂₀N₂O₂ 
• 1393713-37-5 C₁₈⁽¹³⁾CH₂₀N₂O₂ 
• 1393713-11-5 2-(4-isopropoxybenzoyl)cyclohexanone 
• 21762-53-8 N-(2-hydroxybenzoyl)-4-isopropoxybenzamide 
• 1286750-64-8 3-(6-(5-(4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoic acid 
• 1286750-89-7 ethyl 3-(6-(5-(4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate 
• 1286750-87-5 5-(4-isopropoxyphenyl)-3-(5-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)-1,2,4-oxadiazole hydrochloride 

Relevant articles and documents

Design and synthesis of N-(3-sulfamoylphenyl)amides as Trypanosoma brucei leucyl-tRNA synthetase inhibitors

The protozoan parasite Trypanosoma brucei (T. brucei) causes human African trypanosomiasis (HAT), which is a fatal and neglected disease in the tropic areas, and new treatments are urgently needed. Leucyl-tRNA synthetase (LeuRS) is an attractive target for the development of antimicrobial agents. In this work, starting from the hit compound thiourea ZCL539, we designed and synthesized a series of amides as effective T. brucei LeuRS (TbLeuRS) synthetic site inhibitors. The most potent compounds 74 and 91 showed IC50 of 0.24 and 0.25 μM, which were about 700-fold more potent than the starting hit compound. The structure-activity relationship was also discussed. These compounds provided a new scaffold and lead compounds for further development of antitrypanosomal agents.

Novel domino synthesis of 2-(2,3.4-substituted phenyl) quinazolin-4-amine

Convenient domino protocol was developed for the synthesis of 2-arylquinazolin-4-amines by the reaction of N-(2-cyanophenyl) substituted benzimidoyl isothiocyanates with isopropyl amine. The major advantages of this protocol are short reaction times, mild conditions, simple work up, high yields, and pure products. The efficacy of this protocol owes to the competence of synthesis, pure isolation of imidoyl isothiocyanates, and the unique structure conformation of the corresponding intermediate thiourea derivatives.

Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics

Small molecule choline kinase inhibitors having the following formula: are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting choline kinase enzymatic activity, and methods of treating tumors by administering an effective amount of a Formula I compound.